58 studies on Amylin agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment landscape for obesity, potentially offering a more effective therapeutic option than current monotherapies. Cag…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
These findings suggest that PrP-CPP holds significant promise as a novel therapeutic strategy for Type II Diabetes by directly targeting the underlying pathology of IAPP aggregation. By preventing the formation of tox…